{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=4", "query": { "intervention": "matched placebo", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 7009, "total_pages": 701, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T15:25:29.877Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00809354", "title": "Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis", "Arthritis" ], "interventions": [ { "name": "NSAID", "type": "DRUG" }, { "name": "tanezumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2720, "start_date": "2009-02-12", "completion_date": "2011-01-12", "has_results": true, "last_update_posted_date": "2021-06-24", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 250, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809354" }, { "nct_id": "NCT00624065", "title": "Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "carvedilol controlled release/lisinopril", "type": "DRUG" }, { "name": "lisinopril + placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 348, "start_date": "2008-03", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2016-12-28", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 76, "location_summary": "Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Litchifield Park/Arizona", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624065" }, { "nct_id": "NCT07250802", "title": "A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Zasocitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 110, "start_date": "2025-12-04", "completion_date": "2033-01-24", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 11, "location_summary": "Chula Vista, California • Fountain Valley, California • Hialeah, Florida + 8 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Rolling Meadows", "state": "Illinois" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250802" }, { "nct_id": "NCT01453075", "title": "Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis C Infection" ], "interventions": [ { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2011-11", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 1, "location_summary": "Jackson, Mississippi", "locations": [ { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01453075" }, { "nct_id": "NCT00419419", "title": "Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Raynaud's Disease", "Scleroderma", "Autoimmune Diseases" ], "interventions": [ { "name": "Topical AmphiMatrix with nitroglycerin (MQX-503)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediQuest Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-05-30", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 6, "location_summary": "Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00419419" }, { "nct_id": "NCT02624167", "title": "A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Schizophrenia" ], "interventions": [ { "name": "NW-3509A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newron Pharmaceuticals SPA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 90, "start_date": "2015-12", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 2, "location_summary": "Garden Grove, California • Berlin, New Jersey", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02624167" }, { "nct_id": "NCT07639021", "title": "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "NNC0662-0419", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "NNC0662-0419 Placebo", "type": "DRUG" }, { "name": "Semaglutide placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2026-06-09", "completion_date": "2027-06-14", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 24, "location_summary": "Montgomery, Alabama • Costa Mesa, California • Los Angeles, California + 20 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07639021" }, { "nct_id": "NCT04501978", "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "LY3819253", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Remdesivir", "type": "BIOLOGICAL" }, { "name": "VIR-7831", "type": "BIOLOGICAL" }, { "name": "BRII-196/BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442", "type": "BIOLOGICAL" }, { "name": "MP0420", "type": "DRUG" }, { "name": "PF-07304814", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2753, "start_date": "2020-08-04", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 98, "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501978" }, { "nct_id": "NCT03548935", "title": "STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolism and Nutrition Disorder", "Overweight or Obesity" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo (semaglutide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1961, "start_date": "2018-06-04", "completion_date": "2021-03-05", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 39, "location_summary": "Anniston, Alabama • Anaheim, California • Lomita, California + 32 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03548935" }, { "nct_id": "NCT00624468", "title": "Atacicept in Subjects With Optic Neuritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Optic Neuritis" ], "interventions": [ { "name": "Atacicept", "type": "DRUG" }, { "name": "Placebo matched to atacicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 34, "start_date": "2008-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-10-17T15:25:29.877Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "East Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624468" } ] }